Ilmarinen Mutual Pension Insurance Co Acquires 2,500 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ilmarinen Mutual Pension Insurance Co increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 55.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 7,000 shares of the company's stock after purchasing an additional 2,500 shares during the period. Ilmarinen Mutual Pension Insurance Co's holdings in IDEXX Laboratories were worth $2,894,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of IDXX. Hurley Capital LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $29,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $31,000. Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter worth about $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $41,000. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, April 4th. Finally, Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $533.75.

IDEXX Laboratories Trading Up 1.2 %

IDEXX Laboratories stock traded up $4.54 during mid-day trading on Friday, hitting $386.37. 420,583 shares of the stock were exchanged, compared to its average volume of 786,427. The stock has a market capitalization of $31.31 billion, a price-to-earnings ratio of 36.21, a PEG ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm's fifty day simple moving average is $429.51 and its two-hundred day simple moving average is $434.87.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.